• Privacy Policy
  • Contacts
+39 085 295166 info@nsmcongressi.it
Haemosafety Haemosafety
  • Who we are
  • Topics
    • Emerging infections
    • Prion diseases
    • Viral infections: Epidemiology and treatment
    • Security in replacement therapy, pharmacovigilance and haemovigilance
    • Therapeutic advances
    • Zika Virus
  • Link
  • Subscribe to the newsletter
  • en
  • it
Home

Archive for Category: sicurezza terapia

Mar 02 2018

Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?

sicurezza terapia

Patients with blood disorders (including leukemia, platelet function disorders and coagulation factor deficiencies) or...

Read More

Feb 28 2018

Haematology patients and the risk of transfusion transmitted infection

sicurezza terapia

A 2014 study by NHS Blood and Transplant indicated that over one quarter of...

Read More

Feb 26 2018

Parvovirus B19: What Is the Relevance in Transfusion Medicine?

sicurezza terapia

Parvovirus B19 (B19V) has been discovered in 1975. The association with a disease was...

Read More

Feb 21 2018

Transfusion-Transmitted Hepatitis E: NAT Screening of Blood Donations and Infectious Dose

sicurezza terapia

The risk and importance of transfusion-transmitted hepatitis E virus (TT-HEV) infections by contaminated blood...

Read More

Jan 24 2018

Cost projections for implementation of safety interventions to prevent transfusion-transmitted zika virus infection in the United States

sicurezza terapia

In August 2016, the Food and Drug Administration advised US blood centers to screen...

Read More

Jan 22 2018

HEV and transfusion risk

sicurezza terapia

HEV infections are mainly food- and water-borne but transfusion-transmission has occurred in both developing...

Read More

Jan 20 2018

Occult hepatitis B infection and transmission risk through blood transfusion

sicurezza terapia

Over the last decades, the advances in serology and viral nucleic acid testing (NAT)...

Read More

Jan 16 2018

A mathematical model for estimating residual transmission risk of occult hepatitis B virus infection with different blood safety scenarios

sicurezza terapia

Because anti-hepatitis B core antibody testing is not obligatory, blood donors with occult hepatitis...

Read More

Jan 03 2018

The current state of adverse event reporting in hemophilia

sicurezza terapia

Replacement of the missing clotting factor is the mainstay of hemophilia treatment. Whilst historically...

Read More

Nov 28 2017

Effective inactivation of a wide range of viruses by pasteurization

sicurezza terapia

Virus validation guidelines were ultimately developed and issued by the European authorities, requiring manufacturers...

Read More
Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
Next
Copyright © 2021 Non Solo Meeting srl
CCIAA di Pescara n. 93080 - P.iva 01434640684 All Rights Reserved